|
1
|
Wang D, Lu P, Zhang H, Luo M, Zhang X, Wei
X, Gao J, Zhao Z and Liu C: Oct-4 and Nanog promote the
epithelial-mesenchymal transition of breast cancer stem cells and
are associated with poor prognosis in breast cancer patients.
Oncotarget. 5:10803–10815. 2014.PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Suryanarayana Deo SV and Jha D: Role of
Loco-regional surgery in metastatic breast cancer. J Cancer Res
Ther. 9:181–186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Berman AT, Thukral AD, Hwang WT, Solin LJ
and Vapiwala N: Incidence and patterns of distant metastases for
patients with early-stage breast cancer after breast conservation
treatment. Clin Breast Cancer. 13:88–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shanbhogue AK, Karnad AB and Prasad SR:
Tumor response evaluation in oncology: Current update. J Comput
Assist Tomogr. 34:479–484. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coloff JL, Macintyre AN, Nichols AG, Liu
T, Gallo CA, Plas DR and Rathmell JC: Akt-dependent glucose
metabolism promotes Mcl-1 synthesis to maintain cell survival and
resistance to Bcl-2 inhibition. Cancer Res. 71:5204–5213. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wahl RL, Zasadny K, Helvie M, Hutchins GD,
Weber B and Cody R: Metabolic monitoring of breast cancer
chemohormonotherapy using positron emission tomography: Initial
evaluation. J Clin Oncol. 11:2101–2111. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim SJ and Lee SW: Diagnostic accuracy of
18F-FDG PET/CT for detection of peritoneal carcinomatosis; a
systematic review and meta-analysis. Br J Radiol. 91:201705192018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fuss M: Strategies of assessing and
quantifying radiation treatment metabolic tumor response using F18
FDG positron emission tomography (PET). Acta Oncol. 49:948–955.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Humbert O, Cochet A, Riedinger JM,
Berriolo-Riedinger A, Arnould L, Coudert B, Desmoulins I, Toubeau
M, Dygai-Cochet I, Guiu S, et al: HER2-positive breast cancer:
18F-FDG PET for early prediction of response to trastuzumab plus
taxane-based neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging.
41:1525–1533. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Couturier O, Jerusalem G, N'Guyen JM and
Hustinx R: Sequential positron emission tomography using
[18F]fluorodeoxyglucose for monitoring response to chemotherapy in
metastatic breast cancer. Clin Cancer Res. 12:6437–6443. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mortazavi-Jehanno N, Giraudet AL, Champion
L, Lerebours F, Le Stanc E, Edeline V, Madar O, Bellet D, Pecking
AP and Alberini JL: Assessment of response to endocrine therapy
using FDG PET/CT in metastatic breast cancer: A pilot study. Eur J
Nucl Med Mol Imaging. 39:450–460. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu L, Liang S, Yan N, Zhang L, Gu H, Fei
X, Xu Y and Zhang F: Metastatic gastric cancer from breast
carcinoma: A report of 78 cases. Oncol Lett. 14:4069–4077. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Frithiof H, Aaltonen K and Rydén L: A
FISH-based method for assessment of HER-2 amplification status in
breast cancer circulating tumor cells following CellSearch
isolation. Onco Targets Ther. 9:7095–7103. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rousseau C, Devillers A, Sagan C, Ferrer
L, Bridji B, Campion L, Ricaud M, Bourbouloux E, Doutriaux I,
Clouet M, et al: Monitoring of early response to neoadjuvant
chemotherapy in stage II and III breast cancer by
[18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol.
24:5366–5372. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Juweid ME and Cheson BD: Positron-emission
tomography and assessment of cancer therapy. N Engl J Med.
354:496–507. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kidd EA, Siegel BA, Dehdashti F and
Grigsby PW: The standardized uptake value for F-18
fluorodeoxyglucose is a sensitive predictive biomarker for cervical
cancer treatment response and survival. Cancer. 110:1738–1744.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weber WA: Positron emission tomography as
an imaging biomarker. J Clin Oncol. 24:3282–3292. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Larson SM and Schwartz LH: 18F-FDG PET as
a candidate for ‘qualified biomarker’: Functional assessment of
treatment response in oncology. J Nucl Med. 47:901–903.
2006.PubMed/NCBI
|
|
21
|
Ege Aktas G, Taştekin E and Sarikaya A:
Assessment of biological and clinical aggressiveness of invasive
ductal breast cancer using baseline 18F-FDG PET/CT-derived
volumetric parameters. Nucl Med Commun. 39:83–93. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Smith IC, Welch AE, Hutcheon AW, Miller
ID, Payne S, Chilcott F, Waikar S, Whitaker T, Ah-See AK, Eremin O,
et al: Positron emission tomography using
[(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of
breast cancer to primary chemotherapy. J Clin Oncol. 18:1676–1688.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gebhart G, Gámez C, Holmes E, Robles J,
Garcia C, Cortés M, de Azambuja E, Fauria K, Van Dooren V, Aktan G,
et al: 18F-FDG PET/CT for early prediction of response to
neoadjuvant lapatinib, trastuzumab, and their combination in
HER2-positive breast cancer: Results from Neo-ALTTO. J Nucl Med.
54:1862–1868. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Coudert B, Pierga JY, Mouret-Reynier MA,
Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupré PF, Bachelot T,
Gabelle P, et al: Use of [(18)F]-FDG PET to predict response to
neoadjuvant trastuzumab and docetaxel in patients with
HER2-positive breast cancer, and addition of bevacizumab to
neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted
non-responders (AVATAXHER): An open-label, randomised phase 2
trial. Lancet Oncol. 15:1493–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koolen BB, Pengel KE, Wesseling J, Vogel
WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S,
Rutgers EJ and Valdés Olmos RA: FDG PET/CT during neoadjuvant
chemotherapy may predict response in ER-positive/HER2-negative and
triple negative, but not in HER2-positive breast cancer. Breast.
22:691–697. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gennari A, Donati S, Salvadori B,
Giorgetti A, Salvadori PA, Sorace O, Puccini G, Pisani P, Poli M,
Dani D, et al: Role of 2-[18F]-fluorodeoxyglucose (FDG) positron
emission tomography (PET) in the early assessment of response to
chemotherapy in metastatic breast cancer patients. Clin Breast
Cancer. 1:156–163. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tateishi U, Gamez C, Dawood S, Yeung HW,
Cristofanilli M and Macapinlac HA: Bone metastases in patients with
metastatic breast cancer: Morphologic and metabolic monitoring of
response to systemic therapy with integrated PET/CT. Radiology.
247:189–196. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Specht JM, Tam SL, Kurland BF, Gralow JR,
Livingston RB, Linden HM, Ellis GK, Schubert EK, Dunnwald LK and
Mankoff DA: Serial 2-[18F] fluoro-2-deoxy-D-glucose positron
emission tomography (FDG-PET) to monitor treatment of bone-dominant
metastatic breast cancer predicts time to progression (TTP). Breast
Cancer Res Treat. 105:87–94. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Morris PG, Ulaner GA, Eaton A, Fazio M,
Jhaveri K, Patil S, Evangelista L, Park JY, Serna-Tamayo C, Howard
J, et al: Standardized uptake value by positron emission
tomography/computed tomography as a prognostic variable in
metastatic breast cancer. Cancer. 118:5454–5462. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Constantinidou A, Martin A, Sharma B and
Johnston SR: Positron emission tomography/computed tomography in
the management of recurrent/metastatic breast cancer: A large
retrospective study from the Royal Marsden Hospital. Ann Oncol.
22:307–314. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee CI, Gold LS, Nelson HD, Chou R, Ramsey
SD and Sullivan SD: Comparative effectiveness of imaging modalities
to determine metastatic breast cancer treatment response. Breast.
24:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pahk K, Rhee S, Cho J, Seo M, Lee S, Park
T, Park S, Lee E, Park KH, Kim C, et al: The role of interim
18F-FDG PET/CT in predicting early response to neoadjuvant
chemotherapy in breast cancer. Anticancer Res. 34:4447–4455.
2014.PubMed/NCBI
|
|
33
|
Schelling M, Avril N, Nährig J, Kuhn W,
Römer W, Sattler D, Werner M, Dose J, Jänicke F, Graeff H and
Schwaiger M: Positron emission tomography using
[(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in
breast cancer. J Clin Oncol. 18:1689–1695. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wahl RL, Jacene H, Kasamon Y and Lodge MA:
From RECIST to PERCIST: Evolving considerations for PET response
criteria in solid tumors. J Nucl Med. 1 50 Suppl:122S–150S. 2009.
View Article : Google Scholar
|
|
35
|
Kim MK, Ryu JS, Kim SB, Ahn JH, Kim SY,
Park SI, Kim YH, Song HY, Shin JH, Jung HY, et al: Value of
complete metabolic response by (18)F-fluorodeoxyglucose-positron
emission tomography in oesophageal cancer for prediction of
pathologic response and survival after preoperative
chemoradiotherapy. Eur J Cancer. 43:1385–1391. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ott K, Herrmann K, Lordick F, Wieder H,
Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K, et al: Early
metabolic response evaluation by fluorine-18 fluorodeoxyglucose
positron emission tomography allows in vivo testing of
chemosensitivity in gastric cancer: Long-term results of a
prospective study. Clin Cancer Res. 14:2012–2018. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gayed I, Vu T, Iyer R, Johnson M,
Macapinlac H, Swanston N and Podoloff D: The role of 18F-FDG PET in
staging and early prediction of response to therapy of recurrent
gastrointestinal stromal tumors. J Nucl Med. 45:17–21.
2004.PubMed/NCBI
|
|
38
|
Dose Schwarz J, Bader M, Jenicke L,
Hemminger G, Jänicke F and Avril N: Early prediction of response to
chemotherapy in metastatic breast cancer using sequential 18F-FDG
PET. J Nucl Med. 46:1144–1150. 2005.PubMed/NCBI
|
|
39
|
Couturier O, Jerusalem G, N'Guyen JM and
Hustinx R: Sequential positron emission tomography using
[18F]fluorodeoxyglucose for monitoring response to chemotherapy in
metastatic breast cancer. Clin Cancer Res. 12:6437–6443. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Groheux D, Giacchetti S, Hatt M, Marty M,
Vercellino L, de Roquancourt A, Cuvier C, Coussy F, Espié M and
Hindié E: HER2-overexpressing breast cancer: FDG uptake after two
cycles of chemotherapy predicts the outcome of neoadjuvant
treatment. Br J Cancer. 109:1157–1164. 2013. View Article : Google Scholar : PubMed/NCBI
|
